<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04913922</url>
  </required_header>
  <id_info>
    <org_study_id>CA224-065</org_study_id>
    <nct_id>NCT04913922</nct_id>
  </id_info>
  <brief_title>Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML</brief_title>
  <acronym>AARON</acronym>
  <official_title>An Open-Label Phase II Study of Relatlimab (BMS-986016) With Nivolumab (BMS-936558) in Combination With 5-Azacytidine for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older Acute Myeloid Leukemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial will test the safety and tolerability of a combination therapy&#xD;
      (azacitidine in combination with two checkpoint inhibitors, nivolumab [Anti-PD1] and&#xD;
      relatlimab [Anti-LAG3]) in patients with relapsed/refractory Acute Myeloid Leukemia (AML) and&#xD;
      patients ≥ 65 years with initial diagnosis of AML.&#xD;
&#xD;
      Primary objectives are:&#xD;
&#xD;
        -  maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the combination&#xD;
           therapy during the lead-in phase of the clinical trial (6-12 patients) and&#xD;
&#xD;
        -  objective response rate (ORR) of the combination therapy in the phase II part of the&#xD;
           study (up to 24 patients).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>after completion of the first cycle in the fist 6-12 patients, approximately during the first 6-12 months of study conduct</time_frame>
    <description>To determine the MTD of relatlimab in combination with nivolumab and 5-azacytidine in patients with R/R AML.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLTs)</measure>
    <time_frame>after completion of the first cycle in the fist 6-12 patients, approximately during the first 6-12 months of study conduct</time_frame>
    <description>To determine the DLT of relatlimab in combination with nivolumab and 5-azacytidine in patients with R/R AML.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct</time_frame>
    <description>To estimate the ORR to treatment with relatlimab + nivolumab + 5-azacytidine in patients with R/R AML and Patients ≥65 years with initial diagnosis of AML</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematologic improvement</measure>
    <time_frame>During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct</time_frame>
    <description>To determine the number of patients with R/R AML or Patients ≥65 years with initial diagnosis of AML treated with relatlimab + nivolumab + 5-azacytidine who achieve a hematologic improvement (HI) in platelets, hemoglobin, or absolute neutrophil count (ANC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blast reduction</measure>
    <time_frame>During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct</time_frame>
    <description>To determine the number of patients with R/R AML or Patients ≥65 years with initial diagnosis of AML treated with relatlimab + nivolumab + 5-azacytidine who achieve a blast reduction (defined as ≥50% reduction in blast percentage compared to baseline blast percentage in bone marrow)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct</time_frame>
    <description>To assess the duration of response (DOR) of patients with R/R AML or Patients ≥65 years with initial diagnosis of AML treated with relatlimab + nivolumab + 5-azacytidine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct</time_frame>
    <description>To assess the disease-free survival (DFS) of patients with R/R AML or Patients ≥65 years with initial diagnosis of AML treated with relatlimab + nivolumab + 5-azacytidine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct</time_frame>
    <description>To assess the overall survival (OS) of patients with R/R AML or Patients ≥65 years with initial diagnosis of AML treated with relatlimab + nivolumab + 5-azacytidine.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunological changes</measure>
    <time_frame>During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct</time_frame>
    <description>To study immunological changes in the peripheral blood and bone marrow in response to relatlimab + nivolumab + 5-azacytidine therapy, assessed by the frequency of T-cell (subsets), regulatory T cells, and immune checkpoint expression on blasts and T cells by flow cytometry and RNA Sequencing</description>
  </other_outcome>
  <other_outcome>
    <measure>Molecular changes</measure>
    <time_frame>During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct</time_frame>
    <description>To study the methylation status of blast DNA in the peripheral blood and bone marrow in response to relatlimab + nivolumab + 5-azacytidine therapy</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-azacitidine 75 mg/m2 body surface area s.c. for 7 days nivolumab 480mg i.v. day 1 relatlimab 80-160mg i.v. day 1&#xD;
repeat day 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine Injection</intervention_name>
    <description>s.c. 75 mg/m2 BSA for 7 days</description>
    <arm_group_label>Combination therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>480 mg i.v.</description>
    <arm_group_label>Combination therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relatlimab</intervention_name>
    <description>80-160mg i.v.</description>
    <arm_group_label>Combination therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cohort 1 (R/R AML):&#xD;
&#xD;
        - Patients with AML who have failed first line induction chemotherapy (consisting of a&#xD;
        minimum of two intensive chemotherapy cycles, e.g. 7+3 or HAM) or patients with AML who&#xD;
        have relapsed after achieving complete remission (CR), CRi, or CRp, or patients who have&#xD;
        failed up to one prior salvage therapy&#xD;
&#xD;
        Cohort 2 (frontline older AML):&#xD;
&#xD;
        - Patients aged ≥65 years with previously untreated AML who are unfit for or decline&#xD;
        standard induction therapy.&#xD;
&#xD;
        General inclusion criteria:&#xD;
&#xD;
          -  Patients not eligible for intensive induction chemotherapy and/or allogeneic stem cell&#xD;
             transplant.&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  ECOG Performance Status ≤2&#xD;
&#xD;
          -  Adequate organ function:&#xD;
&#xD;
        Total bilirubin ≤2 x ULN (≤3 × ULN if due to leukemic involvement or Gilbert's syndrome)&#xD;
        AST and ALT ≤2.5 × ULN (≤5.0 × ULN if due to leukemic involvement) Serum creatinine ≤2 ×&#xD;
        ULN or glomerular filtration rate (GFR) ≥50 mL/h&#xD;
&#xD;
          -  Adequate cardiac function: TTE with documented LVEF ≥50%&#xD;
&#xD;
          -  At least 2 weeks OR at least 5 half-lives interval from prior treatment to time of&#xD;
             initiation of study medication&#xD;
&#xD;
          -  GvHD of grade ≤A on ≤10 mg prednisone without any additional immunosuppressive&#xD;
             therapies (tacrolimus, ciclosporin, etc.)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Negative pregnancy test and adequate methods of contraception for females of&#xD;
             childbearing potential, adequate methods of contraception for males&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute promyelocytic leukemia (APL)&#xD;
&#xD;
          -  Biphenotypic or bilineage leukemia&#xD;
&#xD;
          -  Known allergy or hypersensitivity to 5-azacytidine, nivolumab, relatlimab, or any of&#xD;
             their components&#xD;
&#xD;
          -  History of life-threatening toxicity related to prior immune therapy&#xD;
&#xD;
          -  Previous treatment with immunotherapeutic drugs targeting PD-1/PD-L1 in combination&#xD;
             with 5-azacytidine&#xD;
&#xD;
          -  Previous treatment with LAG-3 targeted agents&#xD;
&#xD;
          -  Known history of severe interstitial lung disease or severe pneumonitis&#xD;
&#xD;
          -  Known history (active, known, or suspected) of any of the following autoimmune&#xD;
             diseases:&#xD;
&#xD;
        inflammatory bowel disease rheumatoid arthritis systemic progressive sclerosis systemic&#xD;
        lupus erythematosus autoimmune vasculitis&#xD;
&#xD;
          -  Active uncontrolled pneumonitis&#xD;
&#xD;
          -  Active uncontrolled infection&#xD;
&#xD;
          -  Symptomatic or poorly controlled CNS leukemia&#xD;
&#xD;
          -  Confirmed history of encephalitis, meningitis, or uncontrolled seizures in the year&#xD;
             prior to informed consent&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease&#xD;
&#xD;
          -  Troponin T (TnT) or I (TnI) &gt; 2 × institutional ULN&#xD;
&#xD;
          -  Organ allografts&#xD;
&#xD;
          -  Allogeneic hematopoietic stem cell transplantation within the last 100 days before&#xD;
             first study drug administration&#xD;
&#xD;
          -  Active GvHD &gt; grade A&#xD;
&#xD;
          -  Known human immunodeficiency virus seropositivity&#xD;
&#xD;
          -  Known positivity for hepatitis B by surface antigen expression or active hepatitis C&#xD;
             infection&#xD;
&#xD;
          -  Other medical, psychological, or social condition that may interfere with study&#xD;
             participation or compliance, or compromise patient safety&#xD;
&#xD;
          -  Patients unwilling or unable to comply with the protocol&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding&#xD;
&#xD;
          -  Prisoners and subjects who are compulsory detained&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marion Subklewe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine III, University of Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion Subklewe, MD</last_name>
    <phone>+498944000</phone>
    <email>marion.subklewe@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Veit Bücklein, MD</last_name>
    <phone>+498944000</phone>
    <email>veit.buecklein@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital, LMU Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Subklewe, MD</last_name>
      <phone>+49-894400-0</phone>
      <email>marion.subklewe@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Veit Bücklein, MD</last_name>
      <phone>+49-89-4400-0</phone>
      <email>veit.buecklein@med.uni-muenchen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 14, 2021</study_first_submitted>
  <study_first_submitted_qc>May 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>May 30, 2021</last_update_submitted>
  <last_update_submitted_qc>May 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Veit Bücklein</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <keyword>checkpoint blockade</keyword>
  <keyword>immune checkpoint inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

